135 related articles for article (PubMed ID: 15369387)
1. Comparing the conformational behavior of a series of diastereomeric cyclic urea HIV-1 inhibitors using the low mode:monte carlo conformational search method.
Parish CA; Yarger M; Sinclair K; Dure M; Goldberg A
J Med Chem; 2004 Sep; 47(20):4838-50. PubMed ID: 15369387
[TBL] [Abstract][Full Text] [Related]
2. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
3. Solvation studies of DMP323 and A76928 bound to HIV protease: analysis of water sites using grand canonical Monte Carlo simulations.
Marrone TJ; Resat H; Hodge CN; Chang CH; McCammon JA
Protein Sci; 1998 Mar; 7(3):573-9. PubMed ID: 9541388
[TBL] [Abstract][Full Text] [Related]
4. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility.
Zoete V; Michielin O; Karplus M
J Mol Biol; 2002 Jan; 315(1):21-52. PubMed ID: 11771964
[TBL] [Abstract][Full Text] [Related]
5. Cages, baskets, ladders, and tubes: conformational studies of polyhedral oligomeric silsesquioxanes.
Hillson SD; Smith E; Zeldin M; Parish CA
J Phys Chem A; 2005 Sep; 109(37):8371-8. PubMed ID: 16834229
[TBL] [Abstract][Full Text] [Related]
6. Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking.
Huang SY; Zou X
Proteins; 2007 Feb; 66(2):399-421. PubMed ID: 17096427
[TBL] [Abstract][Full Text] [Related]
7. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
[TBL] [Abstract][Full Text] [Related]
8. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.
Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C
J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253
[TBL] [Abstract][Full Text] [Related]
9. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.
Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP
J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627
[TBL] [Abstract][Full Text] [Related]
10. Energetic analyses of chair and boat conformations of maleimide substituted cyclohexane derivatives.
Remmert S; Parish C
J Comput Chem; 2009 Apr; 30(6):992-8. PubMed ID: 18825691
[TBL] [Abstract][Full Text] [Related]
11. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
[TBL] [Abstract][Full Text] [Related]
12. Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.
Wittayanarakul K; Hannongbua S; Feig M
J Comput Chem; 2008 Apr; 29(5):673-85. PubMed ID: 17849388
[TBL] [Abstract][Full Text] [Related]
13. Conformational analysis of trimeric maleimide substituted 1,5,9-triazacyclododecane HIV fusion scaffolds.
Remmert S; Hollis H; Parish CA
Bioorg Med Chem; 2009 Feb; 17(3):1251-8. PubMed ID: 19135378
[TBL] [Abstract][Full Text] [Related]
14. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
15. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
Meagher KL; Carlson HA
J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
[TBL] [Abstract][Full Text] [Related]
16. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
Garg R; Bhhatarai B
Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
[TBL] [Abstract][Full Text] [Related]
19. Conformational flexibility in the flap domains of ligand-free HIV protease.
Heaslet H; Rosenfeld R; Giffin M; Lin YC; Tam K; Torbett BE; Elder JH; McRee DE; Stout CD
Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):866-75. PubMed ID: 17642513
[TBL] [Abstract][Full Text] [Related]
20. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
